Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis by Pers, Yves-Marie et al.
POSTER PRESENTATION Open Access
Longitudinal immunomonitoring following
Tocilizumab in rheumatoid arthritis
Yves-Marie Pers
1,2*, Pascale Louis-Plence
1, Pierre Portales
3, Julie Quentin
1, Sylvie Fabre
1,2, Jean-François Eliaou
3,
Christian Jorgensen
1,2
From 6th European Workshop on Immune-Mediated Inflammatory Diseases
Nice, France. 23-25 November 2011
Introduction
Tocilizumab is a humanized anti-IL-6 receptor monoclo-
nal antibody, which binds to circulating soluble IL-6
receptor and membrane-expressed IL-6 receptor, inhibit-
ing IL-6 binding to both forms of IL-6 receptor. Tocilizu-
mab is an efficient therapy for adults with moderate to
severe RA in whom DMARDs or a TNF inhibitor has
failed. However, the impact of tocilizumab on several
immune populations such as lymphocytes, monocytes,
dendritic cells is still unknown. In order to longitudinally
analyze the variations in frequencies as well as the activa-
tion status of these populations we designed several panels
specific for immune cells and performed immunomonitor-
ing by FACS analyses.
Patients and methods
20 patients with severe and active RA, refractory to meth-
otrexate or anti-TNF therapies were recruited and treated
with 8mg/kg of tocilizumab monthly. Peripheral blood
was recovered for each patient at day 0, as well as 1 and 3
month after informed consents. Staining was performed
on whole blood and Peripheral Blood Mononuclear Cells
were purified for intracellular cytokine staining following
CD3-CD28 overnight stimulation. The data were acquired
on a FACS Canto II (8 colors) and analyzed using DIVA
software. 10 panels specific for sub-populations of T cells
(Th1, Th2, Th17), B cells (naïve, memory and transitional),
monocytes (classical, inflammatory and non-classical) den-
dritic cells (myeloid and plasmacytoid), Tregs (natural and
induced) were designed. The activation status of the T, B
and DC was also monitored.
Results
According to the cytokinic secretion of the T cells follow-
ing ex-vivo activation, we observed various profile of
patients: Th1, Th17 or Th1/Th17. The frequencies of these
pro-inflammatory cytokine secreting T cells were found to
be decreased following treatment with tocilizumab. Con-
cerning the longitudinal analyses of the B cell populations,
an increase of the transitional B cells (CD24
highCD38
high)
was observed in non responder patients and in contrast an
increase of non classical monocytes was observed in good
responders. Concerning the Treg population, the high het-
erogeneity of the patients before treatment was confirmed.
However the CD4CD25FoxP3 staining was confined to
CD127
low and CD62L
high suggesting the induction of
induced Tregs following Tocilizumab treatment as
observed after infliximab treatment.
Conclusion
The design of specific panels to analyse the frequencies
and the activation status of several sub-population of
immune cells, allows a longitudinal monitoring of the
major effector populations in RA patients following cyto-
kine blockade.
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